Dyadic to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025

by B2i | May 1, 2025 | Press Releases

JUPITER, Fla., May 01, 2025 — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a biotechnology company focused on the efficient large-scale manufacture of...

Dyadic to Present at World Vaccine Congress | Washington

by B2i | Apr 16, 2025 | Press Releases

JUPITER, Fla., April 16, 2025 — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a biotechnology company that utilizes its microbial production platforms to...

Dyadic Reports 2024 Year-End Financial Results and Business Updates

by B2i | Mar 26, 2025 | Press Releases

Strong revenue performance, including approximately $1.9 million milestone and license revenue recognized in 2024Up to $7.5 million in grants awarded from CEPI and Gates Foundation intended to accelerate the C1 platform development timeline to manufacture vaccines and...

Dyadic Announces Funding Award from CEPI to Use C1 to Accelerate Development of Protein-Based Vaccines

by B2i | Mar 20, 2025 | Press Releases

JUPITER, Fla., March 20, 2025 — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of...

Dyadic to Report 2024 Full Year Financial Results and Host Conference call on Wednesday, March 26, 2025

by B2i | Mar 12, 2025 | Press Releases

JUPITER, Fla., March 12, 2025 — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a biotechnology company focused on the efficient large-scale manufacture of...

Dyadic to Attend Multiple Industry Events in March

by B2i | Mar 6, 2025 | Press Releases

JUPITER, Fla., March 06, 2025 — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a biotechnology company focused on the efficient large-scale manufacture of...